Acadia Pharmaceuticals Inc.
- ACAD
- NASDAQ
- Biotechnology
- CNS Therapeutics
- Clinical-Stage Biotech
$19.38
Today +1.38%Quote Oct 19, 2026, 02:34 PM UTC
−30.35%over the last month
Max drawdown −32.2%From 1-month high −30.3%3 months −23.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$3.34B
Quote Oct 19
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$29.95
+54.5% from here
Floor
$19.25
0.7% below price
Where the price sits
37 analysts
Analyst range, low to high
$14.50$37.00
- Price $19.38
- Resistance $19.85
- Consensus $29.95
The price is just above its floor and right under resistance. Analysts' average target sits about 55% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ACADPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
797